歌礼制药：在2025年EADV年会报告地尼法司他治疗痤疮的III期研究结果

Core Viewpoint - The company reported significant results from its Phase III study of ASC40 for the treatment of moderate to severe acne, demonstrating substantial improvement compared to placebo [1] Group 1: Company Updates - The company presented its breakthrough research on ASC40 at the 2025 European Academy of Dermatology and Venereology (EADV) annual meeting in Paris [1] - ASC40 achieved all primary, key secondary, and secondary efficacy endpoints in the intention-to-treat (ITT) analysis [1] Group 2: Industry Context - The results indicate a promising advancement in the treatment options available for moderate to severe acne, potentially impacting the dermatology market [1]